Clinical relevance of mutations in patients with myelodysplastic syndromes and myelodysplastic/myeloprolife neoplasms with normal karyotype.

被引：3
|
作者：
Montalban-Bravo, Guillermo
Pierola, Ana Alfonso
Takahashi, Koichi
Konopleva, Marina
Jabbour, Elias
Borthakur, Gautam
Daver, Naval Guastad
Dinardo, Courtney Denton
Estrov, Zeev
Kadia, Tapan M.
Pemmaraju, Naveen
Ravandi, Farhad
Bueso-Ramos, Carlos E.
Kantarjian, Hagop M.
Patel, Keyur
Garcia-Manero, Guillermo
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.7053
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7053
引用
收藏
页数：5
相关论文
共 50 条
  • [21] KARYOTYPE IN MYELODYSPLASTIC SYNDROMES - RELATIONS TO MORPHOLOGY, CLINICAL EVOLUTION, AND SURVIVAL
    BERNASCONI, P
    ALESSANDRINO, EP
    BONI, M
    BONFICHI, M
    MORRA, E
    LAZZARINO, M
    CAMPAGNOLI, C
    ASTORI, C
    AMERICAN JOURNAL OF HEMATOLOGY, 1994, 46 (04) : 270 - 277
  • [22] Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype
    Wang, Wei
    Routbort, Mark J.
    Tang, Zhenya
    Ok, Chi Young
    Patel, Keyur P.
    Daver, Naval
    Garcia-Manero, Guillermo
    Medeiros, L. Jeffrey
    Wang, Sa A.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 99 (06) : 536 - 543
  • [23] MOLECULAR ALTERATIONS ASSOCIATED WITH PROGRESSION OF MYELODYSPLASTIC SYNDROMES TO MYELODYSPLASTIC SYNDROMES/MYELOPROLIFERATIVE NEOPLASMS
    Valencia, A.
    Masala, E.
    Buchi, F.
    Sanna, A.
    Gozzini, A.
    Contini, E.
    Torricelli, F.
    Przychodzen, B.
    Maciejewski, J. P.
    Bosi, A.
    Santini, V.
    HAEMATOLOGICA, 2015, 100 : 54 - 54
  • [24] The relevance of comorbidities in myelodysplastic syndromes
    Stauder, R.
    Wimazal, F.
    Hofer, R.
    Makrai, A.
    Pfeilstoecker, M.
    Noesslinger, T.
    Sperr, W. R.
    Valent, P.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2007, 64 : S33 - S33
  • [25] Mitochondrial tRNA mutations in patients with myelodysplastic syndromes
    Wang, Hui-rui
    Li, Ya-wei
    Wu, Jun-long
    Guo, Shu-li
    MITOCHONDRIAL DNA PART A, 2016, 27 (04) : 2315 - 2317
  • [26] Mitochondrial DNA mutations in patients with myelodysplastic syndromes
    Shin, MG
    Kajigaya, S
    Levin, BC
    Young, NS
    BLOOD, 2003, 101 (08) : 3118 - 3125
  • [27] MUTATIONS IN THE RAS PROTOONCOGENES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
    NEUBAUER, A
    GREENBERG, P
    NEGRIN, R
    GINZTON, N
    LIU, E
    LEUKEMIA, 1994, 8 (04) : 638 - 641
  • [28] Clinical relevance of genetic mutations on treatment response to the demethylating agents in myelodysplastic syndromes.
    Jung, Hyun Ae
    Maeng, Chi Hoon
    Jung, Chul Won
    Jang, Jun Ho
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] Lymphoblastic leukemia following myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms
    Xie, Wei
    Chen, Zhining
    Wang, So A.
    Hu, Shimin
    Li, Shaoying
    Miranda, Roberto N.
    Medeiros, L. Jeffrey
    Tang, Guiling
    LEUKEMIA & LYMPHOMA, 2019, 60 (12) : 2993 - 3001
  • [30] Impact of splicing factor mutations on clinical features in patients with myelodysplastic syndromes
    Naoki Shingai
    Yuka Harada
    Hiroko Iizuka
    Yosuke Ogata
    Noriko Doki
    Kazuteru Ohashi
    Masao Hagihara
    Norio Komatsu
    Hironori Harada
    International Journal of Hematology, 2018, 108 : 598 - 606
12345